Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19

Ruqaiyyah Siddiqui; Naveed Ahmed Khan

doi:10.1021/acschemneuro.0c00288

Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19

Ruqaiyyah Siddiqui
, Naveed Ahmed Khan

American University of Sharjah

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

There is mounting evidence of the central nervous system manifestations associated with COVID-19, particularly in severe cases. Up to 25% of COVID-19 cases exhibit neurological manifestations associated with COVID-19. In view of the devastating nature of the disease due to severe acute respiratory syndrome coronavirus 2, here we debate intranasal drug delivery, in addition to intravenous delivery, as a therapeutic strategy in the management of COVID-19 cases with central nervous system involvement.

Original language	English
Pages (from-to)	1523-1524
Number of pages	2
Journal	ACS Chemical Neuroscience
Volume	11
Issue number	11
DOIs	https://doi.org/10.1021/acschemneuro.0c00288
State	Published - 3 Jun 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
central nervous system
intranasal
neurological manifestation
severe acute respiratory syndrome coronavirus 2

Access to Document

10.1021/acschemneuro.0c00288

Cite this

@article{a6f46c8e962146e3b9d25485dfffbf1d,

title = "Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19",

abstract = "There is mounting evidence of the central nervous system manifestations associated with COVID-19, particularly in severe cases. Up to 25\% of COVID-19 cases exhibit neurological manifestations associated with COVID-19. In view of the devastating nature of the disease due to severe acute respiratory syndrome coronavirus 2, here we debate intranasal drug delivery, in addition to intravenous delivery, as a therapeutic strategy in the management of COVID-19 cases with central nervous system involvement.",

keywords = "COVID-19, central nervous system, intranasal, neurological manifestation, severe acute respiratory syndrome coronavirus 2",

author = "Ruqaiyyah Siddiqui and Khan, \{Naveed Ahmed\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2020 American Chemical Society.",

year = "2020",

month = jun,

day = "3",

doi = "10.1021/acschemneuro.0c00288",

language = "English",

volume = "11",

pages = "1523--1524",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "11",

}

TY - JOUR

T1 - Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19

AU - Siddiqui, Ruqaiyyah

AU - Khan, Naveed Ahmed

PY - 2020/6/3

Y1 - 2020/6/3

N2 - There is mounting evidence of the central nervous system manifestations associated with COVID-19, particularly in severe cases. Up to 25% of COVID-19 cases exhibit neurological manifestations associated with COVID-19. In view of the devastating nature of the disease due to severe acute respiratory syndrome coronavirus 2, here we debate intranasal drug delivery, in addition to intravenous delivery, as a therapeutic strategy in the management of COVID-19 cases with central nervous system involvement.

AB - There is mounting evidence of the central nervous system manifestations associated with COVID-19, particularly in severe cases. Up to 25% of COVID-19 cases exhibit neurological manifestations associated with COVID-19. In view of the devastating nature of the disease due to severe acute respiratory syndrome coronavirus 2, here we debate intranasal drug delivery, in addition to intravenous delivery, as a therapeutic strategy in the management of COVID-19 cases with central nervous system involvement.

KW - COVID-19

KW - central nervous system

KW - intranasal

KW - neurological manifestation

KW - severe acute respiratory syndrome coronavirus 2

UR - https://www.scopus.com/pages/publications/85085748242

U2 - 10.1021/acschemneuro.0c00288

DO - 10.1021/acschemneuro.0c00288

M3 - Review article

C2 - 32432466

AN - SCOPUS:85085748242

SN - 1948-7193

VL - 11

SP - 1523

EP - 1524

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

IS - 11

ER -

Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this